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ABSTRAcT
Background: Evidence shows that the use of protease inhibitors (PIs) in HIV/AIDS 
patients leads to the development of diabetes mellitus. Some degree of insulin resistance 
has also been noted in HIV infected patients not on protease inhibitor therapy and 
this may cause glucose intolerance and overt diabetes mellitus.
Objective: To describe the epidemiological and laboratory characteristics associated 
with diabetes mellitus in HIV positive patients who are HAART naïve.
Design: cross-sectional, cohort analysis of patients with HIV infection on HIV care 
programme.
Setting: Kisumu District Hospital and Mater Hospital.
Subjects: Ten adult patients with HIV infection at initial presentation to the clinic.
Main Outcome Measures: Blood Sugar, cD4+ cell count, body mass index (BMI) , 
alanine transaminase (ALT), aspartate transaminase (AST), serum lipase and amylase 
levels.
Results: one hundred and three patients (60 males and 43 females) were screened. 
Ninety one (57 males, 34 females) patients were excluded because they had normal 
blood sugars. Twelve patients were excluded and out of these, two were further excluded 
due to pancreatitis. Ten patients (three males and seven females) were included in 
the study. The mean age and body mass index was 48.9 years (27-68) and 22.6 kg/M2 
(16.8-28.8) respectively. All patients were HAART naive. Mean fasting blood sugar 
was 17.8 mmol/L (15.4-27.1), mean cD4+ cell count was 236.9 cells/µl (12-885). There 
was no family history of diabetes mellitus. Mean ALT, AST, serum amylase and lipase 
levels were all normal at 34 IU/L, 28.4 IU/L, 76.7 IU/L and 34.96 IU/L respectively. The 
patients were not on diabetogenic drugs or steroids.
Conclusion: Diabetes mellitus is recognised in patients having HIV/AIDS who are 
HAART naïve. They had low mean cD4+ cell count. The body mass indices (BMIs) 
were all normal and all were type II diabetics (T2DM). Adequate screening should 
be done to detect this metabolic syndrome early enough, escpecially where a family 
history of diabetes and other risk factors occur.
INTRoDUcTIoN
While the bulk of evidence suggest that diabetes 
mellitus in HIV/AIDS is associated with protease 
inhibitor (PI) use, there may also be an HIV disease-
associated component in highly active anti-retroviral 
therapy (HAART) naïve HIV positive patients (1-3). 
There is a degree of insulin resistance in patients 
infected with HIV, who are not on PI therapy (4).
 The incidence of overt diabetes mellitus in HIV 
population ranges from as low as 1-2% to as high as 
6-7% (2,3,8), diagnosed on a two hour post-prandial 
blood glucose values > 200 mg/dl (11.1 mmol/L), 
after oral glucose tolerance test (oGTT) (5-7). 
 Pancreatic beta cell function or insulin secretion 
might also be affected by HIV infection or its treatment. 
This causes decreased beta cell responsiveness 
to glucose and subsequent development of overt 
diabetes mellitus (8, 9). HIV infection itself may be 
associated with insulin resistance and truncal obesity. 
Drugs other than PIs which are commonly used in 
the treatment of patients with HIV and may alter 
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glucose metabolism include (4):
Agent Mechanism of action
Glucocorticoid Insulin resistance
Human growth hormone Insulin resistance
Megasterol acetate Insulin resistance
Androgenic steroid Insulin resistance
Pentamidine β cell dysfunction
Didanosine β cell dysfunction
The association of diabetes mellitus and HIV has 
received little attention hence the reason of this 
study.
Inclusion criteria: Patients who presented with signs 
and symptoms suggestive of diabetes mellitus and 
hyperglycaemia in a cohort of HIV positive HAART 
naïve patients.
Exclusion criteria: Patients who were symptomatic for 
diabetes mellitus, were HIV positive, HAART naïve 
and had normal blood sugar levels.
Study: on going prospective, longitudinal, descriptive, 
consecutive entry of patients included in the study.
MATERIALS AND METHoDS
The patients who were HIV positive gave signed 
informed consent for fasting blood sugar test to 
be done. The other parameters assessed included 
height (cm), weight (Kg), (body mass index Kg/
M2), urinalysis, Serum amylase and lipase (to rule 
out pancreatitis seen in HIV patients with or without 
HAART causing glucose metabolism abnormalities) 
and cD4+ cell counts. Alanine transaminase (ALT) 
and aspartate transaminase (AST) were analysed to 
assess any non-alcoholic fatty liver disease (NAfLD) 
correlation which is associated with a degree of 
glucose intolerance. 
 Also included was family history of diabetes 
mellitus, concomitant/chronic drug use which are 
potentially diabetogenic (steroids), history of fatigue, 
blurred vision, weight loss, polyuria and polydipsia. 
further counselling was done and sustained to ensure 
compliance with HAART and oral hypoglycaemic 
agents (oHAs) and advised to be followed up in the 
diabetes outpatient clinic.
 Under aseptic condition, 10 mls whole blood was 
drawn from the cubital vein for analyses of complete 
blood count (cBc), fasting blood sugar and cD4+ 
cell counts, serum amylase and lipase levels and 
AST, ALT levels. Body weight (Kg) was taken using 
the Salter weighing machine, height (cm) was taken 
using the tape measure. Alanine transaminase (ALT) 
and aspartate transaminase (AST) were analysed 
using the reverse passive haemaglutination test assay 
(RPHA), fasting blood sugar (fBS) was analysed using 
a glucometer and complete blood count was done 
using coulter counter machine. cD4+ cell count was 
analysed by fluorescent activated cell sorter (FACS) 
flow cytometry method with a sensitivity of 1-2000 
cells/µl. 
 Urine was also tested by dipstick method.
 The patients who had fasting blood sugars done 
were those who had polyuria, polydipsia, and oral 
candidiasis as pointers to diabetes mellitus.
 one hundred and one (60 males and 41 females) 
were screened, 80 (57 males and 23 females) were 
excluded; they did not have polyuria and polydipsia. 
Twenty one patients were enrolled out of whom nine 
(four males, five females) had normal blood sugars and 
were also excluded. The twelve patients included (four 
males and eight females) had hyperglycaemia.
Intervention: HAART was promptly initiated in 
all the patients (self-purchased and some sent to 
Nairobi Rheumatology clinic (for free HAART). 
oral hypoglycaemic agents glibenclamide and or 
metformin was initiated and the dose adjusted to 
adequate controlling levels. one patient was admitted 
for rehydration; Herpes simplex virus was treated 
with acyclovir, oral candidiasis was treated with 
oral fluconazole and all the patients are on follow 
up at the diabetes out patient clinic (Kisumu District 
Hospital, Nairobi Rheumatology clinic). 
RESULTS
The results are summarised in Table 1. All patients 
were HIV positive and had type II diabetes mellitus. 
The mean fasting blood glucose was 17.8 mmol/L 
(range 15.4 – 27.1) and the normal range is 2.5-6.1 
mmol/l. from the 12 patients with hyperglycaemia, 
two were excluded from the study because they 
had pancreatitis. Their serum amylase and lipase 
levels were 341 IU/L and 500 IU/L and 117 IU/L, 
and 190 IU/L respectively (normal range amylase 
35-118 IU/L and lipase 2.3-50.0 IU/L). one patient 
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had florid angular stomatitis. All the urinalysis tests 
were normal.
 The M:f ratio was 3:7 and mean age was 48.9 
years . The mean fasting blood sugar and cD4+ cell 
count was 17.8 mmol/L (15.4-27.1) and 236.9 cells/
µl (12-885) respectively. Two patients had cD4+ cell 
counts > 350 cells/µl and eight patients had cD4+ 
cell counts < 350 cells/µl. 
 The co-morbidities were herpes zoster virus 1, 
oral candidiasis 10, hypertension 1 and deep venous 
thrombosis (DVT) 1. one patient used commercial 
herbal/vitamin supplements (GNLD) “to boost the 
immunity” while other patients did not have any 
concomitant drug use. No deaths occurred and the 
patients are on follow up at the diabetic outpatient 
clinic.
Table 1
Epidemiological and laboratory characteristics of the 10 patients, who are HAART  naïve,  with diabetes mellitus 
and HIV infection.
Parameter  Mean (Range)
females 7
Males 3
Mean age (years) 48.9 ( 27-68)
Body mass index (Kg/M2) 22.6 (16.8-28.8)
family history of diabetes mellitus NIL
ART use NIL
fasting blood sugar (2.5-6.1 mmol/L) 17.8 (15.4-27.1)
Mean cD4+ cell counts(350-1600 cells/µl) 236.9 (12-885)
cD4+ cell counts > 350 cells/µl 716 (547 and 885)-2 patients.
cD4 + cell counts < 350 cells/µl 117.1 (12-300)-8 patients.
AST (5-37 IU/L) 28.4 (19-37)
ALT (5-40 IU/L) 34.0 (31-89)
Serum amylase (35-118 IU/L) 76.7 ( 50-93)
Serum Lipase (2.3-50.0 IU/L) 34.96 (15-48)
Urinalysis Glycosuria ++++, and bacteria-Nil
concomitant drugs used 9-Nil, 1-commercial herbs/multivitamin supplement.
ART-anti-retroviral therapy 
DIScUSSIoN
Evidence shows that insulin resistance may be 
associated with HIV infection in patients not receiving 
anti-retroviral therapy (ARTs) or protease inhibitors 
(PIs). This case series shows type 2 diabetic patients 
with normal body mass indices (BMI), no family 
history of diabetes mellitus, a low cD4+ cell count 
mean of 236.9 cells/µl and preponderance of oral 
candidiasis as an opportunistic infection. Indeed, oral 
candidiasis has also been shown to be associated with 
low cD4+ cell counts < 200 cells/µl, in studies done 
at Kenyatta National Hospital and Moi Referral and 
Teaching Hospital respectively (10,11). This implies 
that the patients with oral candidiasis should be 
screened for diabetes mellitus and the fasting blood 
sugar level assessed will help elucidate the prevalence 
of diabetes mellitus in HIV/AIDS patients, which is 
currently unknown.
 Evidence shows that regardless of causality, 
there is a high prevalence of insulin resistance in 
patients infected with HIV and a frequently co-
existing dyslipideamia and abdominal obesity, which 
may increase the development of cardiovascular 
morbidity in this population (1, 2, 13, 14). A study 
done in Kenya showed that HIV-infected patients 
at the Kenyatta National Hospital comprehensive 
care clinic demonstrated a high prevalence of 
dyslipidaemia with high levels of total low density 
lipoproteins (LDL) cholesterol and triglycerides 
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(15). As is the case in the general population, the 
prevalence of impaired glucose tolerance (IGT) and 
insulin resistance significantly exceeds the prevalence 
of overt fasting hyperglycaemia (4).
 frank diabetes mellitus could therefore be 
considered only the “tip of the iceberg” in the HIV 
infected and general population and must be actively 
looked for. 
 Deep venous thrombosis (DVT) in  one 
patient and hypertension in two patients, could be 
complications of the diabetes mellitus. The deep 
vein thrombosis (DVT) could also be due to the 
hypercoagulable state due to the severe HIV itself as 
depicted by the low cD4+ cell counts in this cohort 
of patients (16).
 other factors which have been noted to interact in 
the development of diabetes mellitus in HIV infected 
patients include a higher body mass index (BMI > 30 
Kg/M2), higher ALT > 66 IU/L and a strong family 
history of diabetes mellitus (2,3). In this cohort, the 
patients had normal BMI, ALT and AST (implying no 
liver injury) and no positive family history of diabetes 
mellitus. Study done in Kenya showed that most of 
the type 2 dibetics were lean (personal observation– 
c. f. otieno).
 It is noteworthy that HIV infection causes a 
general inflammatory process with the production 
of tumor necrosis factor α and interleukin (IL)-6. 
These may cause inflammation of the pancreas 
and lead to the development of diabetes mellitus. 
Studies should therefore be done to evaluate this 
plausible association. There could also be a direct 
HIV involvement of the pancreas leading to diabetes 
mellitus. 
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